- $19.39m
- $18.53m
- $0.07m
PAVmed Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: NCI-Sponsored Study Shows Positive Data For Lucid Diagnostics' Esoguard® Esophageal Dna Test In Patients Without Symptomatic Gerd
Brief: PAVmed Files Prospectus Relates To Potential Offer, Sale From Time To Time Of 3.3 Million Shares Of Common Stock By Selling Stockholders
Brief: Lucid Diagnostics Announces Closing Of Public Offering Of Common Stock
Lucid Diagnostics tumbles on deep-discounted share sale
Brief: Lucid Diagnostics Announces Pricing Of Public Offering Of Common Stock
Lucid Diagnostics tumbles on stock offering unveil
Brief: Lucid Diagnostics Announces Proposed Public Offering Of Common Stock
Brief: Pavmed Inc Files For Offering Of 3.3 Million Shares Of Common Stock
Brief: PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
PAVmed Inc reports results for the quarter ended December 31 - Earnings Summary
PAVmed Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering
Brief: Lucid Diagnostics Announces $15.3 Million Registered Direct Offering
Brief: Tasso Partners Reports 18.9% Passive Stake In PAVmed As Of Feb 21 - SEC Filing
Brief: PAVmed Regains Compliance With Nasdaq Stockholders' Equity Requirement
Brief: Pavmed Inc Files For Mixed Shelf Offering Of Up To $125 Million
PAVmed Inc reports results for the quarter ended September 30 - Earnings Summary
PAVmed Inc expected to post earnings of $1.98 a share - Earnings Preview